Back to MPLN Home Client Services: +1 865.380.9746

PDGFRB 5q32 Rearrangement

Test ID: F PDGFRB CPT Code: 88374 (if automated read), 88377 (if manual read)
Expected Turnaround Time
5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
FISH test on hematologic specimens for detection PDGFRB (5q32) gene rearrangement. PDGFRB rearrangement may be observed in chronic myeloproliferative disorders (CMPD), myelodysplastic/myeloproliferative syndromes (MDS/MPD) and AML, frequently associated with eosinophilia and splenomegaly. Often ordered as part of the F EOSINOPHILA Panel.
Requisition Forms
Oncology Pathology Requisition

Specimen Requirements

Specimen Requirements
  • Whole Blood: 5 mL, EDTA preferred (NaHep accepted)
  • Bone Marrow Aspirate: 3 mL, EDTA preferred (NaHep accepted)
Specimen Stability

72 hours

Storage Requirements
  • Whole Blood: 2°C to 25°C
  • Bone Marrow Aspirate: 2°C to 25°C
  • Fixed Cytogenetically Prepared Cells: -28°C to -15°C
Shipping Conditions
Ambient, Refrigerated
Shipping Recommendations

AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen. Do not freeze.

Specimen Rejection Criteria

Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells

Test Details

Synonyms

platelet-derived growth factor receptor-beta, JTK12, CD140B, 5q32-33, PDGFRβ

Keywords
Fluorescence in-situ Hybridization, Leukemia, Oncology, Oncology FISH Probes, Myeloproliferative Disease (MPD), Genomics
Test Method
Fluorescence in situ hybridization (FISH)
Methodology Category
FISH
Regulatory Status
ASR
Special Considerations

All attempts will be made to process and report samples received > 72 hours post-collection.  Bone marrow is the sample of choice in most heme malignancies.

Associations

chronic myeloproliferative disorders with eosinophilia, chronic myelomonocytic leukemia, tyrosine kinase inhibitors